| 主权项 |
1. A method for treating an autoimmune disease or condition, a heteroimmune disease or condition, or an inflammatory disease or condition comprising administering to a patient in need a therapeutically effective amount of a compound of Formula (I) having the structure: wherein:
R1 is halogen, —CN, —OH, —NH2, —SH, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C4alkoxy, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted heteroaryl or substituted or unsubstituted C3-C8cycloalkyl;G is substituted or unsubstituted C2-C4alkenyl, substituted or unsubstituted C2-C4alkynyl, substituted or unsubstituted C3-C8cycloalkyl, substituted or unsubstituted C1-C4alkoxy, substituted or unsubstituted C1-C4heteroalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, halogen, —CN, —NO2, —OH, —OCF3, —OCH2F, —OCF2H, —CF3, —SCH3, —N(R21)S(═O)2R23, S(═O)2N(R21)(R22), —S(═O)R23, —S(═O)2R23, —C(═O)R23, —OC(═O)R23, —CO2R21, N(R21)(R22), —C(═O)N(R21)(R22), —N(R21)C(═O)R23, N(R21)C(═O)OR22, N(R21)C(═O)N(R21)(R22), or La-Ar;La is a bond, —CH2—, —CH(OH)—, —C(O)—, —CH2O—, —OCH2—, —SCH2, —CH2S—, —N(R21)—, —N(R21)C(O)—, —C(O)N(R21)—, —N(R21)C(O)N(R21)—, —O—, —S—, —S(O)2—, —N(R21)S(O)2—, or —S(O)2N(R21)—;Ar is a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;each R24 is independently halogen, —CN, —NO2, —OH, —OCF3, —OCH2F, —OCF2H, —CF3, —SCH3, —N(R21)S(═O)2R23, S(═O)2N(R21)(R22), —S(═O)R23, —S(═O)2R23, —C(═O)R23, —OC(═O)R23, —CO2R21, N(R21)(R22), —C(═O)N(R21)(R22), —N(R21)C(═O)R23, N(R21)C(═O)OR22, —N(R21)C(═O)N(R21)(R22), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted cycloalkyl;each R21 and R22 is independently H, substituted or unsubstituted C1-C6alkyl, or substituted or unsubstituted C3-C8cycloalkyl;each R23 is each independently substituted or unsubstituted C1-C6alkyl, or substituted or unsubstituted C3-C8cycloalkyl;n is 0-4;Y is an optionally substituted group selected from among C1-C6alkylene, C1-C6heteroalkylene, C6-C12arylene, C3-C12heteroarylene, C1-C6alkyleneC6-C12arylene, C1-C6alkyleneC3-C12heteroarylene, C1-C6alkyleneC3-C8cycloalkylene, C1-C6alkyleneC2-C7heterocycloalkylene, C3-C8cycloalkylene, C2-C7heterocycloalkylene, fused C3-C8cycloalkyleneC2-C7heterocycloalkylene, and spiro C3-C8cycloalkyleneC2-C7heterocycloalkylene;Z is —C(═O)—, —N(Ra)C(═O)—, or —N(Ra)S(═O)x—, where x is 1 or 2, and Ra is H, substituted or unsubstituted C1-C6alkyl, or substituted or unsubstituted C3—C cycloalkyl;R6 is H or L-J-W;R7 and R8 are independently H or L-J-W; or R7 and R8 taken together form a bond;L and J are each independently a bond, substituted or unsubstituted C1-C6alkylene, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted C1-C6heteroalkylene, substituted or unsubstituted C2-C7heterocycloalkylene, substituted or unsubstituted C6-C12arylene, substituted or unsubstituted C3-C12heteroarylene, —CO—, —O—, or —S—;W is H, or NR25R26; andR25 and R26 are each independently H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3—C cycloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, or substituted or unsubstituted C3-C12heteroaryl; or a pharmaceutically acceptable solvate, or a pharmaceutically acceptable salt thereof. |
